Trending...
- Healthi Life, Bangkok's Urban Longevity House, Honoured at Asia-Pacific Awards 2025
- Christmas Miracle Chronicles - New movie coming up this holiday season !
- Webtronix Designs Web Agency Launches "LocalFind" to Revolutionize AI Local SEO for Local Businesses
MALVERN, Pa.--(BUSINESS WIRE)--YPrime, LLC., a global leader in cloud-based eClinical solutions, announced today the launch of their fifth-generation electronic clinical outcome assessment (eCOA) platform. YPrime's newest platform features an improved user experience for patients, clinical investigators, sponsors, and CROs. This advanced technology enhances clinical trial efficiency, increases site satisfaction, and improves patient compliance. This release also ensures the delivery of cleaner data, streamlining the clinical trial data collection and approval process.
"With a 15-year track record as a technology leader, we are constantly innovating to help drive the digital transformation of clinical research," said YPrime Co-Founder and CEO Shawn Blackburn. "The rapid shift toward a more patient-centered approach to clinical trials is enabled by the strength of our eCOA platform."
More on The PennZone
Tailored for today's complex clinical trials, YPrime's platform helps patients remain engaged and compliant through straightforward design. Developed to integrate intelligently with other eClinical technologies and with the ability to move between devices, YPrime offers a customized solution with the necessary control and security that ensures accurate data collection from specification to submission.
"Real-time data access enhances project control for sponsors and empowers their decision-making," said Michael Hughes, senior vice president, product development. "With superior processing power and advanced security protections, clinical development teams can be assured that they'll receive continuous, high-quality data throughout the duration of the study."
About YPrime
YPrime's cloud-based technology streamlines clinical trial data collection and management. YPrime's eCOA and interactive response technology (IRT) platforms introduce greater speed, precision, and data quality to clinical trials. Our consulting services help clients simplify downstream processes, while moving faster and more efficiently to their next development milestone.
"With a 15-year track record as a technology leader, we are constantly innovating to help drive the digital transformation of clinical research," said YPrime Co-Founder and CEO Shawn Blackburn. "The rapid shift toward a more patient-centered approach to clinical trials is enabled by the strength of our eCOA platform."
More on The PennZone
- Sylvester Anthony III Introduces His Artist Journey with Debut Single "Cherish"
- Boston Industrial Solutions Introduces High-Performance Primer for Bonding Liquid Silicone to Epoxy
- Together We Thrive: Kingdom Life Health & Career Fair Unites Faith, Wellness and Opportunity
- Healthcare Leaders Publish New Integrated Behavioral Healthcare Guide, Led by Doctors of Behavioral Health
- Verbica Challenges Panetta to a Televised Debate on the Issues
Tailored for today's complex clinical trials, YPrime's platform helps patients remain engaged and compliant through straightforward design. Developed to integrate intelligently with other eClinical technologies and with the ability to move between devices, YPrime offers a customized solution with the necessary control and security that ensures accurate data collection from specification to submission.
"Real-time data access enhances project control for sponsors and empowers their decision-making," said Michael Hughes, senior vice president, product development. "With superior processing power and advanced security protections, clinical development teams can be assured that they'll receive continuous, high-quality data throughout the duration of the study."
About YPrime
YPrime's cloud-based technology streamlines clinical trial data collection and management. YPrime's eCOA and interactive response technology (IRT) platforms introduce greater speed, precision, and data quality to clinical trials. Our consulting services help clients simplify downstream processes, while moving faster and more efficiently to their next development milestone.
0 Comments
Latest on The PennZone
- $20 Million Revenue Target, Accelerating Growth, 7% Of Outstanding Shares Retired, Clear Path Toward Profitability: VSee Health, Inc N A S D A Q: VSEE
- HomeCentris Home Health Achieves 5-Star CMS Rating
- Adsoptia Launches AI-Powered Optimization Platform for a New Era of Autonomous Marketing Decisions
- Heritage at Manalapan Announces New Incentive: Included Finished Basement on Select Homesites
- Leicester UK Manufacturer Tabletop Tyrant Secures Flawless 100% Customer Satisfaction Rating Across 5,800+ Orders
- The Calida Group Announces Promotion of Joshua Nelson to President, Advancing Next Phase of National Growth
- Cango Mobility x Hikvision Announce Strategic Partnership
- Institute of Emerging Minds Publishes Framework for Glymphatic Clearance and Cognitive Optimization
- HomeCentris Healthcare Signs Definitive Agreement to Acquire S&K Holdings, Expanding Mid Atlantic Platform
- Nayarit Strengthens Its Position as a Global Surf Destination; Sayulita to Become Mexico's First Official Surf City
- Century Fasteners de Mexico Exhibiting at 2026 Farnborough International Airshow
- George Martinez Completes Community Re-distribution Initiative, Returning $5,000 In Campaign Resources To Anchorage Nonprofits
- Mister Omaha Tries The Turf At Lone Star Park
- Andrew D. Levine Releases The Lily Network, an Indian Noir Mystery of Power, Paperwork & Murder
- The Mapping Software Behind America's Viral Maps Just Got Faster and Smarter
- Longevityresearch.ca publishes cross-disease causal analysis quantifying endpoint reduction across 27 diseases
- Joulescope JS320 Launches to Help Engineers Develop Battery-Powered Devices with Greater Confidence
- Ghanaian Afrobeat Artist Praise Kusi Announces Upcoming EP "After 21:00" Releasing July 3, 2026
- Translational Scientist Roohid Parast Comments on FDA Approval of Icotrokinra for Psoriasis
- TURRENTINE: A Family Legacy United Through Music